120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
支气管镜热蒸汽消融亚肺段给药准确性与结局的关联：严重异质性肺气肿中的探索性回顾性研究
Authors Yang H, Chen S, Zheng X, Cui N, Xie F, Hou H, Ye L, Herth FJF , Sun J
Received 13 August 2025
Accepted for publication 12 January 2026
Published 23 January 2026 Volume 2026:21 560457
DOI https://doi.org/10.2147/COPD.S560457
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Vanesa Bellou
Han Yang,1,* Si Chen,2,3,* Xiaoxuan Zheng,2,3,* Ningxin Cui,1 Fangfang Xie,2,3 Huan Hou,2,3 Lin Ye,2,3 Felix J F Herth,4,5 Jiayuan Sun1– 3
1Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Department of Respiratory Endoscopy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 3Shanghai Engineering Research Center of Respiratory Endoscopy, Shanghai, People’s Republic of China; 4Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany; 5Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
*These authors contributed equally to this work
Correspondence: Jiayuan Sun, Department of Respiratory Endoscopy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People’s Republic of China, Email xkyyjysun@163.com Felix J F Herth, Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, 69126, Germany, Email felix.herth@med.uni-heidelberg.de
Purpose: Bronchoscopic thermal vapor ablation (BTVA) is a minimally invasive treatment for severe emphysema. However, the treatment doses are typically generated at the segmental level. In specific cases, treatment needs to be conducted at the subsegmental level, and the proportion can only be roughly allocated based on CT image review, potentially leading to dose mismatch. This retrospective exploratory study investigated the relationship between subsegmental dose accuracy (theoretical-to-actual matching) and clinical outcomes following BTVA.
Methods: Patients who underwent BTVA at the Shanghai Chest Hospital between 2023 and 2024 were analyzed. Subsegmental theoretical doses (BroncQCT software) were compared to previously administered actual treatment doses. Dose matching was defined as: 1) segmental treatments were presumed matched (uniform vapor assumption), 2) subsegmental treatments required ≤ 10% deviation between actual and theoretical dose ratios (|Actual ratio - Theoretical ratio| × 100%). Patients with > 10% deviation or BroncQCT-identified nontarget subsegments were unmatched. Clinical parameters at 1, 3, 6, and 12 months after single treatment were compared.
Results: Among 21 patients (15 matched, 6 unmatched), the mean changes in FEV1 for the overall cohort were +70mL at 1 month (n = 19, P = 0.018), +90mL at 3 months (n = 14, P = 0.056), and +130mL at 6 months (n = 8, P = 0.015). The matched group demonstrated superior median increases compared to unmatched patients (+150mL [n = 9] vs +10mL [n = 5]; P = 0.012) at 3 months where between-group differences were maximal. Similar trends were observed at 1 month (median +110mL [n = 14] vs 0mL [n = 5]; P = 0.044) and 6 months (median +150mL [n = 5] vs +60mL [n = 3]; P = 0.036). Adverse events (including two late deaths in comorbid patients) were documented, though small sample sizes prevent definitive safety conclusions.
Conclusion: This exploratory study found that subsegmental dose matching was associated with greater FEV1 changes after BTVA. These hypothesis-generating findings require prospective validation in a randomized controlled trial (NCT06152107).
Keywords: bronchoscopic thermal vapor ablation, BTVA, chronic obstructive pulmonary disease, COPD, emphysema, bronchoscopic lung volume reduction, BLVR
1Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Department of Respiratory Endoscopy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 3Shanghai Engineering Research Center of Respiratory Endoscopy, Shanghai, People’s Republic of China; 4Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany; 5Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
*These authors contributed equally to this work
Correspondence: Jiayuan Sun, Department of Respiratory Endoscopy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People’s Republic of China, Email xkyyjysun@163.com Felix J F Herth, Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, 69126, Germany, Email felix.herth@med.uni-heidelberg.de
Purpose: Bronchoscopic thermal vapor ablation (BTVA) is a minimally invasive treatment for severe emphysema. However, the treatment doses are typically generated at the segmental level. In specific cases, treatment needs to be conducted at the subsegmental level, and the proportion can only be roughly allocated based on CT image review, potentially leading to dose mismatch. This retrospective exploratory study investigated the relationship between subsegmental dose accuracy (theoretical-to-actual matching) and clinical outcomes following BTVA.
Methods: Patients who underwent BTVA at the Shanghai Chest Hospital between 2023 and 2024 were analyzed. Subsegmental theoretical doses (BroncQCT software) were compared to previously administered actual treatment doses. Dose matching was defined as: 1) segmental treatments were presumed matched (uniform vapor assumption), 2) subsegmental treatments required ≤ 10% deviation between actual and theoretical dose ratios (|Actual ratio - Theoretical ratio| × 100%). Patients with > 10% deviation or BroncQCT-identified nontarget subsegments were unmatched. Clinical parameters at 1, 3, 6, and 12 months after single treatment were compared.
Results: Among 21 patients (15 matched, 6 unmatched), the mean changes in FEV1 for the overall cohort were +70mL at 1 month (n = 19, P = 0.018), +90mL at 3 months (n = 14, P = 0.056), and +130mL at 6 months (n = 8, P = 0.015). The matched group demonstrated superior median increases compared to unmatched patients (+150mL [n = 9] vs +10mL [n = 5]; P = 0.012) at 3 months where between-group differences were maximal. Similar trends were observed at 1 month (median +110mL [n = 14] vs 0mL [n = 5]; P = 0.044) and 6 months (median +150mL [n = 5] vs +60mL [n = 3]; P = 0.036). Adverse events (including two late deaths in comorbid patients) were documented, though small sample sizes prevent definitive safety conclusions.
Conclusion: This exploratory study found that subsegmental dose matching was associated with greater FEV1 changes after BTVA. These hypothesis-generating findings require prospective validation in a randomized controlled trial (NCT06152107).
Keywords: bronchoscopic thermal vapor ablation, BTVA, chronic obstructive pulmonary disease, COPD, emphysema, bronchoscopic lung volume reduction, BLVR